Akcea

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
Xconomy
FDA
Pfizer
tafamidis
Vyndaqel
Vyndamax
ATTR
Alnylam
Akcea
Flag link:
AbbVie, Akcea benefit from latest CHMP recommendations
AbbVie, Akcea benefit from latest CHMP recommendations
Biopharma Dive
Europe
CHMP
AbbVie
Akcea
Biomarin
Sanofi
Pfizer
drug approvals
Flag link:
Early November Brings More Quarterly Reports
Early November Brings More Quarterly Reports
BioSpace
earnings
Akcea
Mylan
Eli Lilly
Regeneron
Flag link:
FDA clears rare disease therapy from Akcea, Ionis
FDA clears rare disease therapy from Akcea, Ionis
Biopharma Dive
FDA
Akcea
Ionis Pharmaceuticals
Tegsedi
Onpattro
Alnylam
hATTR amyloidosis
Flag link:
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
CP Wire
Akcea
hereditary ATTR amyloidosis
FDA
inotersen
Alnylam
Patisiran
Flag link:
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms
Xconomy
Ionis Pharmaceuticals
Akcea
Alnylam
transthyretin amyloidosis
inotersen
IONIS-TTR-Lrx
Flag link:
Ionis-spinout Akcea prices IPO below expected range
Ionis-spinout Akcea prices IPO below expected range
Drug Delivery Business News
Akcea
Ionis
IPOs
Volanesorsen
Flag link:
Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch
Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch
Endpoints
Akcea
biotech
IPOs
Novartis
Flag link: